<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029185</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-1984-01</org_study_id>
    <secondary_id>FD-R-001984-01</secondary_id>
    <nct_id>NCT00029185</nct_id>
  </id_info>
  <brief_title>Study of Dehydrex in Patients With Corneal Erosion</brief_title>
  <official_title>Topical Dehydrex in Treating Recurrent Corneal Erosion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holles Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a compassionate-use treatment study to provide Dehydrex to patients with corneal&#xD;
      erosion syndrome who have previously used Dehydrex.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study continues to provide Dehydrex to patients who have received it previously under&#xD;
      other studies. Patients continue to be treated with their current dose of Dehydrex. Upward&#xD;
      dose adjustments may be made as clinically indicated. Patients undergo eye exams every 3 to 4&#xD;
      months or more often. Downward dose titration will be attempted in patients who are stable,&#xD;
      free of symptoms, and willing to attempt downward adjustments. In patients who are able to&#xD;
      discontinue the medication, duration of healing will be determined. In those patients who&#xD;
      experience a recurrence after discontinuing the medication, Dehydrex will be restarted at a&#xD;
      dose higher than the minimum effective dose. After at least 8 weeks of treatment and&#xD;
      resolution of symptoms, the dose may again be reduced. Further attempts to discontinue the&#xD;
      medication will not be made.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>September 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Corneal Diseases</condition>
  <condition>Recurrence</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydrex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Clinical diagnosis of symptomatic recurrent corneal syndrome due to anterior membrane&#xD;
             dystrophy or posttraumatic abrasion&#xD;
&#xD;
          -  Not responsive to standard medical therapy with artificial tears, hypertonic saline,&#xD;
             or bandage soft contact lenses&#xD;
&#xD;
          -  At least 3 episodes of erosion within the past 4 months documented by slit lamp&#xD;
             examination&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Allergy to any component of the medications to be used&#xD;
&#xD;
          -  Active ocular surface infection due to bacteria, virus, or fungus&#xD;
&#xD;
          -  Chronic atopic disease affecting the ocular surface or adnexa&#xD;
&#xD;
          -  Dry eye, exposure, trichiasis, entropion, ectropion, or neurotrophic keratopathy&#xD;
&#xD;
          -  Concurrent use of contact lenses&#xD;
&#xD;
          -  Diagnosis of persistent epithelial defect in eye to be treated&#xD;
&#xD;
          -  Concurrent use of topical medication to eye to be treated&#xD;
&#xD;
          -  Any ocular eyelid surgery within the past 6 months&#xD;
&#xD;
          -  Pre-existing corneal stromal edema&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Postsurgical infection&#xD;
&#xD;
          -  Dry eye condition of 16 or greater on Patient's Dry Eye Questionnaire&#xD;
&#xD;
          -  Other investigational medications within the past 6 months&#xD;
&#xD;
          -  Other corneal dystrophy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Holles Laboratories, Inc.</name>
      <address>
        <city>Cohasset</city>
        <state>Massachusetts</state>
        <zip>02025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2001</verification_date>
  <study_first_submitted>January 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 8, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2002</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Corneal Erosion</keyword>
  <keyword>Dextrans</keyword>
  <keyword>Administration, Topical</keyword>
  <keyword>Ophthalmic Solutions</keyword>
  <keyword>Thimerosal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

